Class I evidence that, in adults with AChRAb+ ocular or generalized myasthenia gravis (MG) on stable standard-of-care therapy and currently using pyridostigmine, pyridostigmine improves MG symptoms compared with placebo.

This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.